Pharmacokinetics of arundic acid, an astrocyte modulating agent, in acute ischemic stroke

Hideyasu Ishibashi, L. Creed Pettigrew, Yosuke Funakoshi, Makoto Hiramatsu

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Arundic acid is an astrocyte modulating agent that improves neurological outcome in experimental acute stroke models. The pharmacokinetics of arundic acid in patients with acute ischemic stroke was investigated in a randomized, double-blind study. Six groups of 8 to 9 patients each received 2, 4, 6, 8, 10, or 12 mg/kg/h of arundic acid for a daily 1-hour infusion until completion of 7 doses. Maximum plasma concentrations of arundic acid increased with increasing dose; however, the systemic exposure was less than dose proportional at higher doses. The mean terminal half-life was approximately 2 to 3 hours. There was no excessive accumulation in plasma. Although systemic exposure in elderly patients was 30% greater than that in younger patients, the plasma concentration returned to nearly or below the limit of quantification prior to next administration. The pharmacokinetics of arundic acid in acute stroke patients assessed in this study were similar to that in healthy adults.

Original languageEnglish
Pages (from-to)445-452
Number of pages8
JournalJournal of Clinical Pharmacology
Issue number4
StatePublished - Apr 2007


  • Arundic acid
  • Astrocyte
  • Cerebral ischemia
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Pharmacokinetics of arundic acid, an astrocyte modulating agent, in acute ischemic stroke'. Together they form a unique fingerprint.

Cite this